Validation of the AJCC TNM Substaging of pT2 Bladder Cancer: Deep Muscle Invasion Is Associated with Significantly Worse Outcome

Derya Tilki, Oliver Reich, Pierre I. Karakiewicz, Giacomo Novara, Wassim Kassouf, Süleyman Ergün, Yves Fradet, Vincenzo Ficarra, Guru Sonpavde, Christian G. Stief, Eila Skinner, Robert S. Svatek, Yair Lotan, Arthur I Sagalowsky, Shahrokh F. Shariat

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Background: The current TNM bladder cancer staging system stratifies bladder muscle invasion into superficial (pT2a) and deep (pT2b). Controversy exists regarding the significance of the extent of muscle invasion on clinical outcome. Objective: Our aim was to compare the cancer-specific outcomes of patients with pT2 urothelial carcinoma of the bladder (UCB) at radical cystectomy (RC) in a large international cohort of patients. Design, setting, and participants: The records of patients treated with RC for UCB at six centers were reviewed. Of the 2605 reviewed patients, 565 (21.7%) had pT2 disease. None of the patients received preoperative systemic chemotherapy or radiotherapy. Measurements: Patients' characteristics and outcome were evaluated. Results and limitations: The median patient age in the entire group was 66.2 yr. Of the 565 patients with pT2 UCB, 249 patients (44.1%) had substage pT2a; 316 patients (55.9%) had pT2b. One hundred and eleven patients (19.6%) had metastases to regional lymph nodes. Median follow-up was 50.5 mo. Recurrence-free survival (73.2% vs 58.7%) and cancer-specific survival (78.0% vs 65.1%) estimates were significantly better for pT2a patients compared with those with pT2b (p = 0.002 and p = 0.001, respectively). Pathologic T2 substaging was associated with worse recurrence-free and cancer-specific survival after adjusting for the effects of standard pathologic features (p = 0.011 and p = 0.006, respectively). The statistical significance of these associations was reconfirmed in subgroup analysis limited to those patients with pathologically negative lymph nodes. Conclusions: In this large international cohort, pathologic substaging helped to stratify patients with lymph node-negative pT2 UCB into statistically significantly different risk groups. These data support the value of the current American Joint Committee on Cancer TNM staging.

Original languageEnglish (US)
Pages (from-to)112-117
Number of pages6
JournalEuropean Urology
Volume58
Issue number1
DOIs
StatePublished - Jul 2010

Fingerprint

Muscle Neoplasms
Urinary Bladder Neoplasms
Urinary Bladder
Neoplasm Staging
Carcinoma
Cystectomy
Lymph Nodes
Survival
Recurrence
Muscles
Neoplasms

Keywords

  • AJCC stage
  • Prognosis
  • Substaging
  • Survival
  • Urinary bladder
  • Urothelial carcinoma

ASJC Scopus subject areas

  • Urology

Cite this

Tilki, D., Reich, O., Karakiewicz, P. I., Novara, G., Kassouf, W., Ergün, S., ... Shariat, S. F. (2010). Validation of the AJCC TNM Substaging of pT2 Bladder Cancer: Deep Muscle Invasion Is Associated with Significantly Worse Outcome. European Urology, 58(1), 112-117. https://doi.org/10.1016/j.eururo.2010.01.015

Validation of the AJCC TNM Substaging of pT2 Bladder Cancer : Deep Muscle Invasion Is Associated with Significantly Worse Outcome. / Tilki, Derya; Reich, Oliver; Karakiewicz, Pierre I.; Novara, Giacomo; Kassouf, Wassim; Ergün, Süleyman; Fradet, Yves; Ficarra, Vincenzo; Sonpavde, Guru; Stief, Christian G.; Skinner, Eila; Svatek, Robert S.; Lotan, Yair; Sagalowsky, Arthur I; Shariat, Shahrokh F.

In: European Urology, Vol. 58, No. 1, 07.2010, p. 112-117.

Research output: Contribution to journalArticle

Tilki, D, Reich, O, Karakiewicz, PI, Novara, G, Kassouf, W, Ergün, S, Fradet, Y, Ficarra, V, Sonpavde, G, Stief, CG, Skinner, E, Svatek, RS, Lotan, Y, Sagalowsky, AI & Shariat, SF 2010, 'Validation of the AJCC TNM Substaging of pT2 Bladder Cancer: Deep Muscle Invasion Is Associated with Significantly Worse Outcome', European Urology, vol. 58, no. 1, pp. 112-117. https://doi.org/10.1016/j.eururo.2010.01.015
Tilki, Derya ; Reich, Oliver ; Karakiewicz, Pierre I. ; Novara, Giacomo ; Kassouf, Wassim ; Ergün, Süleyman ; Fradet, Yves ; Ficarra, Vincenzo ; Sonpavde, Guru ; Stief, Christian G. ; Skinner, Eila ; Svatek, Robert S. ; Lotan, Yair ; Sagalowsky, Arthur I ; Shariat, Shahrokh F. / Validation of the AJCC TNM Substaging of pT2 Bladder Cancer : Deep Muscle Invasion Is Associated with Significantly Worse Outcome. In: European Urology. 2010 ; Vol. 58, No. 1. pp. 112-117.
@article{75bdb174b78a47658523a1ff5fcfce0a,
title = "Validation of the AJCC TNM Substaging of pT2 Bladder Cancer: Deep Muscle Invasion Is Associated with Significantly Worse Outcome",
abstract = "Background: The current TNM bladder cancer staging system stratifies bladder muscle invasion into superficial (pT2a) and deep (pT2b). Controversy exists regarding the significance of the extent of muscle invasion on clinical outcome. Objective: Our aim was to compare the cancer-specific outcomes of patients with pT2 urothelial carcinoma of the bladder (UCB) at radical cystectomy (RC) in a large international cohort of patients. Design, setting, and participants: The records of patients treated with RC for UCB at six centers were reviewed. Of the 2605 reviewed patients, 565 (21.7{\%}) had pT2 disease. None of the patients received preoperative systemic chemotherapy or radiotherapy. Measurements: Patients' characteristics and outcome were evaluated. Results and limitations: The median patient age in the entire group was 66.2 yr. Of the 565 patients with pT2 UCB, 249 patients (44.1{\%}) had substage pT2a; 316 patients (55.9{\%}) had pT2b. One hundred and eleven patients (19.6{\%}) had metastases to regional lymph nodes. Median follow-up was 50.5 mo. Recurrence-free survival (73.2{\%} vs 58.7{\%}) and cancer-specific survival (78.0{\%} vs 65.1{\%}) estimates were significantly better for pT2a patients compared with those with pT2b (p = 0.002 and p = 0.001, respectively). Pathologic T2 substaging was associated with worse recurrence-free and cancer-specific survival after adjusting for the effects of standard pathologic features (p = 0.011 and p = 0.006, respectively). The statistical significance of these associations was reconfirmed in subgroup analysis limited to those patients with pathologically negative lymph nodes. Conclusions: In this large international cohort, pathologic substaging helped to stratify patients with lymph node-negative pT2 UCB into statistically significantly different risk groups. These data support the value of the current American Joint Committee on Cancer TNM staging.",
keywords = "AJCC stage, Prognosis, Substaging, Survival, Urinary bladder, Urothelial carcinoma",
author = "Derya Tilki and Oliver Reich and Karakiewicz, {Pierre I.} and Giacomo Novara and Wassim Kassouf and S{\"u}leyman Erg{\"u}n and Yves Fradet and Vincenzo Ficarra and Guru Sonpavde and Stief, {Christian G.} and Eila Skinner and Svatek, {Robert S.} and Yair Lotan and Sagalowsky, {Arthur I} and Shariat, {Shahrokh F.}",
year = "2010",
month = "7",
doi = "10.1016/j.eururo.2010.01.015",
language = "English (US)",
volume = "58",
pages = "112--117",
journal = "European Urology",
issn = "0302-2838",
publisher = "Elsevier",
number = "1",

}

TY - JOUR

T1 - Validation of the AJCC TNM Substaging of pT2 Bladder Cancer

T2 - Deep Muscle Invasion Is Associated with Significantly Worse Outcome

AU - Tilki, Derya

AU - Reich, Oliver

AU - Karakiewicz, Pierre I.

AU - Novara, Giacomo

AU - Kassouf, Wassim

AU - Ergün, Süleyman

AU - Fradet, Yves

AU - Ficarra, Vincenzo

AU - Sonpavde, Guru

AU - Stief, Christian G.

AU - Skinner, Eila

AU - Svatek, Robert S.

AU - Lotan, Yair

AU - Sagalowsky, Arthur I

AU - Shariat, Shahrokh F.

PY - 2010/7

Y1 - 2010/7

N2 - Background: The current TNM bladder cancer staging system stratifies bladder muscle invasion into superficial (pT2a) and deep (pT2b). Controversy exists regarding the significance of the extent of muscle invasion on clinical outcome. Objective: Our aim was to compare the cancer-specific outcomes of patients with pT2 urothelial carcinoma of the bladder (UCB) at radical cystectomy (RC) in a large international cohort of patients. Design, setting, and participants: The records of patients treated with RC for UCB at six centers were reviewed. Of the 2605 reviewed patients, 565 (21.7%) had pT2 disease. None of the patients received preoperative systemic chemotherapy or radiotherapy. Measurements: Patients' characteristics and outcome were evaluated. Results and limitations: The median patient age in the entire group was 66.2 yr. Of the 565 patients with pT2 UCB, 249 patients (44.1%) had substage pT2a; 316 patients (55.9%) had pT2b. One hundred and eleven patients (19.6%) had metastases to regional lymph nodes. Median follow-up was 50.5 mo. Recurrence-free survival (73.2% vs 58.7%) and cancer-specific survival (78.0% vs 65.1%) estimates were significantly better for pT2a patients compared with those with pT2b (p = 0.002 and p = 0.001, respectively). Pathologic T2 substaging was associated with worse recurrence-free and cancer-specific survival after adjusting for the effects of standard pathologic features (p = 0.011 and p = 0.006, respectively). The statistical significance of these associations was reconfirmed in subgroup analysis limited to those patients with pathologically negative lymph nodes. Conclusions: In this large international cohort, pathologic substaging helped to stratify patients with lymph node-negative pT2 UCB into statistically significantly different risk groups. These data support the value of the current American Joint Committee on Cancer TNM staging.

AB - Background: The current TNM bladder cancer staging system stratifies bladder muscle invasion into superficial (pT2a) and deep (pT2b). Controversy exists regarding the significance of the extent of muscle invasion on clinical outcome. Objective: Our aim was to compare the cancer-specific outcomes of patients with pT2 urothelial carcinoma of the bladder (UCB) at radical cystectomy (RC) in a large international cohort of patients. Design, setting, and participants: The records of patients treated with RC for UCB at six centers were reviewed. Of the 2605 reviewed patients, 565 (21.7%) had pT2 disease. None of the patients received preoperative systemic chemotherapy or radiotherapy. Measurements: Patients' characteristics and outcome were evaluated. Results and limitations: The median patient age in the entire group was 66.2 yr. Of the 565 patients with pT2 UCB, 249 patients (44.1%) had substage pT2a; 316 patients (55.9%) had pT2b. One hundred and eleven patients (19.6%) had metastases to regional lymph nodes. Median follow-up was 50.5 mo. Recurrence-free survival (73.2% vs 58.7%) and cancer-specific survival (78.0% vs 65.1%) estimates were significantly better for pT2a patients compared with those with pT2b (p = 0.002 and p = 0.001, respectively). Pathologic T2 substaging was associated with worse recurrence-free and cancer-specific survival after adjusting for the effects of standard pathologic features (p = 0.011 and p = 0.006, respectively). The statistical significance of these associations was reconfirmed in subgroup analysis limited to those patients with pathologically negative lymph nodes. Conclusions: In this large international cohort, pathologic substaging helped to stratify patients with lymph node-negative pT2 UCB into statistically significantly different risk groups. These data support the value of the current American Joint Committee on Cancer TNM staging.

KW - AJCC stage

KW - Prognosis

KW - Substaging

KW - Survival

KW - Urinary bladder

KW - Urothelial carcinoma

UR - http://www.scopus.com/inward/record.url?scp=77952883914&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77952883914&partnerID=8YFLogxK

U2 - 10.1016/j.eururo.2010.01.015

DO - 10.1016/j.eururo.2010.01.015

M3 - Article

C2 - 20097469

AN - SCOPUS:77952883914

VL - 58

SP - 112

EP - 117

JO - European Urology

JF - European Urology

SN - 0302-2838

IS - 1

ER -